About
David Buchsbaum is a finance executive and investment-banking professional serving as Chief Financial Officer of ADvantage Therapeutics, an Alzheimer's-focused biotech company. He is also listed as Managing Director of Investment Banking at Dawson James and previously worked in equity research and portfolio-related roles, including managing work connected to the Holtzman Opportunity Fund and Jewelcor private equity holdings. His background spans healthcare/biotech banking, consumer equity research, and public-company investor relations.
Areas of interest
biotechhealthcareAlzheimer's diseaseneurodegenerationinvestment bankingequity researchconsumer discretionaryshareholder activismprivate equity